nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—CXCL8—psoriasis	0.336	1	CbGaD
Tolmetin—osteoarthritis—Prednisone—psoriasis	0.271	1	CpDpCtD
Tolmetin—MPO—Calcipotriol—psoriasis	0.214	0.749	CbGbCtD
Tolmetin—PTGS2—Triamcinolone—psoriasis	0.0223	0.078	CbGbCtD
Tolmetin—PTGS2—Betamethasone—psoriasis	0.0192	0.067	CbGbCtD
Tolmetin—SLC22A6—Cyclosporine—psoriasis	0.0125	0.0438	CbGbCtD
Tolmetin—PTGS2—Dexamethasone—psoriasis	0.0111	0.0389	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—psoriasis	0.00663	0.0232	CbGbCtD
Tolmetin—PTGS2—skeletal joint—psoriasis	0.000656	0.216	CbGeAlD
Tolmetin—MPO—endothelium—psoriasis	0.000511	0.169	CbGeAlD
Tolmetin—PTGS2—synovial membrane of synovial joint—psoriasis	0.000498	0.164	CbGeAlD
Tolmetin—Indomethacin—CXCL8—psoriasis	0.000469	0.591	CrCbGaD
Tolmetin—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000351	0.157	CbGdCrCtD
Tolmetin—Indomethacin—PPARG—psoriasis	0.000324	0.409	CrCbGaD
Tolmetin—PTGS2—skin epidermis—psoriasis	0.000319	0.105	CbGeAlD
Tolmetin—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000281	0.126	CbGdCrCtD
Tolmetin—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000273	0.122	CbGdCrCtD
Tolmetin—CXCL8—Allograft Rejection—IL12B—psoriasis	0.00025	0.00593	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—HLA-E—psoriasis	0.000244	0.00579	CbGpPWpGaD
Tolmetin—PTGS1—endothelium—psoriasis	0.000243	0.0799	CbGeAlD
Tolmetin—CXCL8—EBV LMP1 signaling—NFKB1—psoriasis	0.00024	0.0057	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—CAT—psoriasis	0.00024	0.00568	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—CRP—psoriasis	0.00024	0.00568	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000237	0.00562	CbGpPWpGaD
Tolmetin—PTGS2—endothelium—psoriasis	0.000232	0.0764	CbGeAlD
Tolmetin—MPO—IL23-mediated signaling events—NFKB1—psoriasis	0.000222	0.00525	CbGpPWpGaD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000221	0.00523	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—ICAM1—psoriasis	0.00022	0.00522	CbGpPWpGaD
Tolmetin—MPO—skin of body—psoriasis	0.000218	0.0719	CbGeAlD
Tolmetin—CXCL8—Overview of nanoparticle effects—TNF—psoriasis	0.000218	0.00516	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000215	0.0051	CbGpPWpGaD
Tolmetin—CXCL8—TSLP Signaling Pathway—NFKBIA—psoriasis	0.000213	0.00504	CbGpPWpGaD
Tolmetin—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000212	0.0948	CbGdCrCtD
Tolmetin—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000211	0.005	CbGpPWpGaD
Tolmetin—MPO—Vitamin B12 Metabolism—IFNG—psoriasis	0.000206	0.00488	CbGpPWpGaD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IL12B—psoriasis	0.000204	0.00484	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—IL10—psoriasis	0.000202	0.00478	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—STAT3—psoriasis	0.000199	0.00472	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—IL4—psoriasis	0.000196	0.00465	CbGpPWpGaD
Tolmetin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000191	0.00453	CbGpPWpGaD
Tolmetin—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000191	0.00453	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—CRP—psoriasis	0.00019	0.00451	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000189	0.00448	CbGpPWpGaD
Tolmetin—CXCL8—EBV LMP1 signaling—TNF—psoriasis	0.000187	0.00443	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—TNFAIP3—psoriasis	0.000185	0.00439	CbGpPWpGaD
Tolmetin—CXCL8—Peptide ligand-binding receptors—CCL20—psoriasis	0.000184	0.00435	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—IL10—psoriasis	0.000183	0.00434	CbGpPWpGaD
Tolmetin—CXCL8—GPCR ligand binding—HCAR2—psoriasis	0.000181	0.00428	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—NDUFA5—psoriasis	0.000179	0.00424	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—IL4—psoriasis	0.000178	0.00422	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—HLA-A—psoriasis	0.000178	0.00421	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—NOS2—psoriasis	0.000177	0.0042	CbGpPWpGaD
Tolmetin—CXCL8—Overview of nanoparticle effects—IL6—psoriasis	0.000176	0.00417	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—ICAM1—psoriasis	0.000175	0.00415	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—HLA-B—psoriasis	0.000174	0.00413	CbGpPWpGaD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000174	0.00412	CbGpPWpGaD
Tolmetin—Hepatitis—Mycophenolic acid—psoriasis	0.000173	0.00297	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—psoriasis	0.000173	0.00297	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IL4—psoriasis	0.000173	0.0041	CbGpPWpGaD
Tolmetin—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000173	0.00409	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—TNF—psoriasis	0.000172	0.00408	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Calcitriol—psoriasis	0.000172	0.00295	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—VEGFA—psoriasis	0.000172	0.00407	CbGpPWpGaD
Tolmetin—MPO—Vitamin B12 Metabolism—NFKB1—psoriasis	0.000171	0.00406	CbGpPWpGaD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—psoriasis	0.000171	0.00405	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL13—psoriasis	0.00017	0.00402	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Dexamethasone—psoriasis	0.00017	0.00291	CcSEcCtD
Tolmetin—Cardiac failure congestive—Betamethasone—psoriasis	0.00017	0.00291	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000169	0.076	CbGdCrCtD
Tolmetin—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000169	0.076	CbGdCrCtD
Tolmetin—Abdominal discomfort—Cyclosporine—psoriasis	0.000168	0.00288	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—IFNG—psoriasis	0.000168	0.00397	CbGpPWpGaD
Tolmetin—Glossitis—Methotrexate—psoriasis	0.000168	0.00287	CcSEcCtD
Tolmetin—Urticaria—Calcitriol—psoriasis	0.000167	0.00286	CcSEcCtD
Tolmetin—Visual impairment—Mycophenolic acid—psoriasis	0.000167	0.00286	CcSEcCtD
Tolmetin—Somnolence—Acitretin—psoriasis	0.000167	0.00285	CcSEcCtD
Tolmetin—Abdominal pain—Calcitriol—psoriasis	0.000166	0.00285	CcSEcCtD
Tolmetin—Body temperature increased—Calcitriol—psoriasis	0.000166	0.00285	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—NFKBIA—psoriasis	0.000166	0.00394	CbGpPWpGaD
Tolmetin—Dyspepsia—Acitretin—psoriasis	0.000165	0.00282	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000165	0.0738	CbGdCrCtD
Tolmetin—Dysuria—Cyclosporine—psoriasis	0.000164	0.00281	CcSEcCtD
Tolmetin—Visual disturbance—Dexamethasone—psoriasis	0.000162	0.00278	CcSEcCtD
Tolmetin—Visual disturbance—Betamethasone—psoriasis	0.000162	0.00278	CcSEcCtD
Tolmetin—Tinnitus—Mycophenolic acid—psoriasis	0.000162	0.00277	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—HLA-A—psoriasis	0.000161	0.00382	CbGpPWpGaD
Tolmetin—Constipation—Acitretin—psoriasis	0.00016	0.00274	CcSEcCtD
Tolmetin—Dysuria—Mycophenolate mofetil—psoriasis	0.00016	0.00274	CcSEcCtD
Tolmetin—Weight increased—Cyclosporine—psoriasis	0.000159	0.00273	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IL12B—psoriasis	0.000159	0.00378	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Betamethasone—psoriasis	0.000159	0.00272	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Dexamethasone—psoriasis	0.000159	0.00272	CcSEcCtD
Tolmetin—Weight decreased—Cyclosporine—psoriasis	0.000159	0.00271	CcSEcCtD
Tolmetin—Dizziness—Methoxsalen—psoriasis	0.000156	0.00267	CcSEcCtD
Tolmetin—Weight increased—Mycophenolate mofetil—psoriasis	0.000156	0.00266	CcSEcCtD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000155	0.00368	CbGpPWpGaD
Tolmetin—CXCL8—G alpha (i) signalling events—CCL20—psoriasis	0.000155	0.00367	CbGpPWpGaD
Tolmetin—Weight decreased—Mycophenolate mofetil—psoriasis	0.000155	0.00265	CcSEcCtD
Tolmetin—Renal failure—Cyclosporine—psoriasis	0.000154	0.00263	CcSEcCtD
Tolmetin—Gastrointestinal pain—Acitretin—psoriasis	0.000153	0.00262	CcSEcCtD
Tolmetin—Stomatitis—Cyclosporine—psoriasis	0.000152	0.00261	CcSEcCtD
Tolmetin—TDO2—Metabolism—CYP2S1—psoriasis	0.000152	0.0036	CbGpPWpGaD
Tolmetin—Urinary tract infection—Cyclosporine—psoriasis	0.000152	0.0026	CcSEcCtD
Tolmetin—Asthenia—Calcitriol—psoriasis	0.000151	0.00259	CcSEcCtD
Tolmetin—Vascular purpura—Prednisone—psoriasis	0.00015	0.00257	CcSEcCtD
Tolmetin—Renal failure—Mycophenolate mofetil—psoriasis	0.00015	0.00256	CcSEcCtD
Tolmetin—Haematuria—Cyclosporine—psoriasis	0.000149	0.00255	CcSEcCtD
Tolmetin—Urticaria—Acitretin—psoriasis	0.000149	0.00255	CcSEcCtD
Tolmetin—Flatulence—Mycophenolic acid—psoriasis	0.000149	0.00255	CcSEcCtD
Tolmetin—Stomatitis—Mycophenolate mofetil—psoriasis	0.000149	0.00254	CcSEcCtD
Tolmetin—Urinary tract infection—Mycophenolate mofetil—psoriasis	0.000148	0.00254	CcSEcCtD
Tolmetin—Abdominal pain—Acitretin—psoriasis	0.000148	0.00254	CcSEcCtD
Tolmetin—Body temperature increased—Acitretin—psoriasis	0.000148	0.00254	CcSEcCtD
Tolmetin—Headache—Methoxsalen—psoriasis	0.000148	0.00253	CcSEcCtD
Tolmetin—Cardiac failure congestive—Prednisone—psoriasis	0.000148	0.00253	CcSEcCtD
Tolmetin—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000148	0.00253	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—HLA-DRB1—psoriasis	0.000147	0.00349	CbGpPWpGaD
Tolmetin—Epistaxis—Cyclosporine—psoriasis	0.000147	0.00252	CcSEcCtD
Tolmetin—Oedema—Hydroxyurea—psoriasis	0.000147	0.00252	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000146	0.00347	CbGpPWpGaD
Tolmetin—Haematuria—Mycophenolate mofetil—psoriasis	0.000145	0.00249	CcSEcCtD
Tolmetin—Weight increased—Prednisolone—psoriasis	0.000145	0.00248	CcSEcCtD
Tolmetin—Diarrhoea—Calcitriol—psoriasis	0.000144	0.00247	CcSEcCtD
Tolmetin—Thrombocytopenia—Hydroxyurea—psoriasis	0.000144	0.00247	CcSEcCtD
Tolmetin—Epistaxis—Mycophenolate mofetil—psoriasis	0.000144	0.00246	CcSEcCtD
Tolmetin—Agranulocytosis—Mycophenolate mofetil—psoriasis	0.000142	0.00244	CcSEcCtD
Tolmetin—Weight increased—Hydrocortisone—psoriasis	0.000142	0.00243	CcSEcCtD
Tolmetin—Weight decreased—Hydrocortisone—psoriasis	0.000141	0.00241	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000141	0.00334	CbGpPWpGaD
Tolmetin—Nausea—Methoxsalen—psoriasis	0.00014	0.0024	CcSEcCtD
Tolmetin—Hepatitis—Cyclosporine—psoriasis	0.00014	0.0024	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—NFKB1—psoriasis	0.00014	0.0033	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—IL6—psoriasis	0.000139	0.0033	CbGpPWpGaD
Tolmetin—Purpura—Prednisone—psoriasis	0.000139	0.00238	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—ICAM1—psoriasis	0.000137	0.00325	CbGpPWpGaD
Tolmetin—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000137	0.00325	CbGpPWpGaD
Tolmetin—Hepatitis—Mycophenolate mofetil—psoriasis	0.000137	0.00234	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—JUN—psoriasis	0.000136	0.00323	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—IFNG—psoriasis	0.000136	0.00322	CbGpPWpGaD
Tolmetin—CXCL8—TSLP Signaling Pathway—NFKB1—psoriasis	0.000136	0.00322	CbGpPWpGaD
Tolmetin—Visual impairment—Cyclosporine—psoriasis	0.000135	0.00231	CcSEcCtD
Tolmetin—Asthenia—Acitretin—psoriasis	0.000134	0.0023	CcSEcCtD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000134	0.00318	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Prednisone—psoriasis	0.000134	0.0023	CcSEcCtD
Tolmetin—Vomiting—Calcitriol—psoriasis	0.000134	0.00229	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—CD4—psoriasis	0.000134	0.00316	CbGpPWpGaD
Tolmetin—Weight increased—Triamcinolone—psoriasis	0.000133	0.00228	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—TNF—psoriasis	0.000133	0.00316	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—IFNG—psoriasis	0.000133	0.00316	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—PCNA—psoriasis	0.000133	0.00315	CbGpPWpGaD
Tolmetin—Headache—Calcitriol—psoriasis	0.000132	0.00226	CcSEcCtD
Tolmetin—Visual impairment—Mycophenolate mofetil—psoriasis	0.000132	0.00226	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—psoriasis	0.000131	0.00225	CcSEcCtD
Tolmetin—Tinnitus—Cyclosporine—psoriasis	0.000131	0.00224	CcSEcCtD
Tolmetin—Somnolence—Hydroxyurea—psoriasis	0.000131	0.00224	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—SOCS1—psoriasis	0.00013	0.00308	CbGpPWpGaD
Tolmetin—CXCL8—Bladder Cancer—TP53—psoriasis	0.00013	0.00308	CbGpPWpGaD
Tolmetin—Dyspepsia—Hydroxyurea—psoriasis	0.000129	0.00222	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—IL4—psoriasis	0.000129	0.00306	CbGpPWpGaD
Tolmetin—Chest pain—Mycophenolic acid—psoriasis	0.000129	0.0022	CcSEcCtD
Tolmetin—Diarrhoea—Acitretin—psoriasis	0.000128	0.00219	CcSEcCtD
Tolmetin—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000128	0.0574	CbGdCrCtD
Tolmetin—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000128	0.0574	CbGdCrCtD
Tolmetin—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000128	0.00219	CcSEcCtD
Tolmetin—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000128	0.00303	CbGpPWpGaD
Tolmetin—Tinnitus—Mycophenolate mofetil—psoriasis	0.000128	0.00218	CcSEcCtD
Tolmetin—Constipation—Hydroxyurea—psoriasis	0.000126	0.00215	CcSEcCtD
Tolmetin—Nausea—Calcitriol—psoriasis	0.000125	0.00214	CcSEcCtD
Tolmetin—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000125	0.0561	CbGdCrCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000124	0.00294	CbGpPWpGaD
Tolmetin—Dizziness—Acitretin—psoriasis	0.000124	0.00212	CcSEcCtD
Tolmetin—Dizziness—Fluocinolone Acetonide—psoriasis	0.000124	0.00211	CcSEcCtD
Tolmetin—Epistaxis—Triamcinolone—psoriasis	0.000123	0.00211	CcSEcCtD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000123	0.00292	CbGpPWpGaD
Tolmetin—Oedema—Mycophenolic acid—psoriasis	0.000123	0.00211	CcSEcCtD
Tolmetin—Visual impairment—Prednisolone—psoriasis	0.000123	0.00211	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—STAT3—psoriasis	0.000122	0.00289	CbGpPWpGaD
Tolmetin—Weight increased—Dexamethasone—psoriasis	0.000121	0.00207	CcSEcCtD
Tolmetin—Weight increased—Betamethasone—psoriasis	0.000121	0.00207	CcSEcCtD
Tolmetin—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000121	0.00206	CcSEcCtD
Tolmetin—Weight decreased—Dexamethasone—psoriasis	0.00012	0.00206	CcSEcCtD
Tolmetin—Weight decreased—Betamethasone—psoriasis	0.00012	0.00206	CcSEcCtD
Tolmetin—Flatulence—Cyclosporine—psoriasis	0.00012	0.00206	CcSEcCtD
Tolmetin—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.00012	0.00285	CbGpPWpGaD
Tolmetin—Vomiting—Acitretin—psoriasis	0.000119	0.00204	CcSEcCtD
Tolmetin—Vomiting—Fluocinolone Acetonide—psoriasis	0.000119	0.00203	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—IFNG—psoriasis	0.000119	0.00281	CbGpPWpGaD
Tolmetin—Visual disturbance—Methotrexate—psoriasis	0.000118	0.00202	CcSEcCtD
Tolmetin—CXCL8—IL-3 Signaling Pathway—STAT3—psoriasis	0.000118	0.0028	CbGpPWpGaD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000118	0.00279	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—JUN—psoriasis	0.000118	0.00279	CbGpPWpGaD
Tolmetin—Flatulence—Mycophenolate mofetil—psoriasis	0.000117	0.00201	CcSEcCtD
Tolmetin—Headache—Acitretin—psoriasis	0.000117	0.00201	CcSEcCtD
Tolmetin—Headache—Fluocinolone Acetonide—psoriasis	0.000117	0.002	CcSEcCtD
Tolmetin—Body temperature increased—Hydroxyurea—psoriasis	0.000116	0.00199	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Methotrexate—psoriasis	0.000116	0.00198	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—NFKBIA—psoriasis	0.000114	0.00271	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000113	0.00267	CbGpPWpGaD
Tolmetin—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000111	0.00264	CbGpPWpGaD
Tolmetin—Nausea—Acitretin—psoriasis	0.000111	0.0019	CcSEcCtD
Tolmetin—Nausea—Fluocinolone Acetonide—psoriasis	0.000111	0.0019	CcSEcCtD
Tolmetin—MPO—Selenium Micronutrient Network—NFKB1—psoriasis	0.000111	0.00263	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—JUN—psoriasis	0.00011	0.00261	CbGpPWpGaD
Tolmetin—Somnolence—Mycophenolic acid—psoriasis	0.00011	0.00187	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—LEP—psoriasis	0.000109	0.00259	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—TNF—psoriasis	0.000109	0.00257	CbGpPWpGaD
Tolmetin—Dyspepsia—Mycophenolic acid—psoriasis	0.000108	0.00186	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IFNG—psoriasis	0.000108	0.00255	CbGpPWpGaD
Tolmetin—MPO—Vitamin B12 Metabolism—IL6—psoriasis	0.000108	0.00255	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL10—psoriasis	0.000106	0.00252	CbGpPWpGaD
Tolmetin—CXCL8—LPA receptor mediated events—NFKB1—psoriasis	0.000106	0.00251	CbGpPWpGaD
Tolmetin—Asthenia—Hydroxyurea—psoriasis	0.000106	0.00181	CcSEcCtD
Tolmetin—Weight increased—Prednisone—psoriasis	0.000105	0.00181	CcSEcCtD
Tolmetin—Constipation—Mycophenolic acid—psoriasis	0.000105	0.0018	CcSEcCtD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.000105	0.00249	CbGpPWpGaD
Tolmetin—Weight decreased—Prednisone—psoriasis	0.000105	0.00179	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IFNG—psoriasis	0.000105	0.00248	CbGpPWpGaD
Tolmetin—Chest pain—Cyclosporine—psoriasis	0.000104	0.00178	CcSEcCtD
Tolmetin—PTGS1—skin of body—psoriasis	0.000104	0.0341	CbGeAlD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—psoriasis	0.000103	0.00244	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—ICAM1—psoriasis	0.000103	0.00243	CbGpPWpGaD
Tolmetin—Visual impairment—Dexamethasone—psoriasis	0.000103	0.00176	CcSEcCtD
Tolmetin—Visual impairment—Betamethasone—psoriasis	0.000103	0.00176	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—JUN—psoriasis	0.000103	0.00243	CbGpPWpGaD
Tolmetin—CXCL8—GPCR downstream signaling—HCAR2—psoriasis	0.000102	0.00242	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—NOS2—psoriasis	0.000102	0.00241	CbGpPWpGaD
Tolmetin—Chest pain—Mycophenolate mofetil—psoriasis	0.000101	0.00174	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—psoriasis	0.000101	0.00173	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000101	0.00172	CcSEcCtD
Tolmetin—Diarrhoea—Hydroxyurea—psoriasis	0.000101	0.00172	CcSEcCtD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.0001	0.00238	CbGpPWpGaD
Tolmetin—Oedema—Cyclosporine—psoriasis	9.97e-05	0.00171	CcSEcCtD
Tolmetin—Anaphylactic shock—Cyclosporine—psoriasis	9.97e-05	0.00171	CcSEcCtD
Tolmetin—PTGS2—skin of body—psoriasis	9.9e-05	0.0326	CbGeAlD
Tolmetin—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	9.82e-05	0.00233	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Cyclosporine—psoriasis	9.76e-05	0.00167	CcSEcCtD
Tolmetin—Body temperature increased—Mycophenolic acid—psoriasis	9.74e-05	0.00167	CcSEcCtD
Tolmetin—Abdominal pain—Mycophenolic acid—psoriasis	9.74e-05	0.00167	CcSEcCtD
Tolmetin—Dizziness—Hydroxyurea—psoriasis	9.73e-05	0.00166	CcSEcCtD
Tolmetin—Oedema—Mycophenolate mofetil—psoriasis	9.72e-05	0.00166	CcSEcCtD
Tolmetin—Anaphylactic shock—Mycophenolate mofetil—psoriasis	9.72e-05	0.00166	CcSEcCtD
Tolmetin—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	9.7e-05	0.0023	CbGpPWpGaD
Tolmetin—MPO—Folate Metabolism—TP53—psoriasis	9.57e-05	0.00227	CbGpPWpGaD
Tolmetin—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	9.55e-05	0.00226	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Mycophenolate mofetil—psoriasis	9.52e-05	0.00163	CcSEcCtD
Tolmetin—CXCL8—GPCR ligand binding—CCL20—psoriasis	9.39e-05	0.00222	CbGpPWpGaD
Tolmetin—Vomiting—Hydroxyurea—psoriasis	9.35e-05	0.0016	CcSEcCtD
Tolmetin—Abdominal discomfort—Methotrexate—psoriasis	9.28e-05	0.00159	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—HCAR2—psoriasis	9.27e-05	0.0022	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	9.22e-05	0.00218	CbGpPWpGaD
Tolmetin—Headache—Hydroxyurea—psoriasis	9.21e-05	0.00158	CcSEcCtD
Tolmetin—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	9.09e-05	0.00215	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Prednisolone—psoriasis	9.07e-05	0.00155	CcSEcCtD
Tolmetin—Oedema—Prednisolone—psoriasis	9.07e-05	0.00155	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—psoriasis	9.06e-05	0.00155	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—JUN—psoriasis	9.04e-05	0.00214	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—NFKBIA—psoriasis	8.93e-05	0.00212	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.86e-05	0.0021	CbGpPWpGaD
Tolmetin—Somnolence—Cyclosporine—psoriasis	8.86e-05	0.00152	CcSEcCtD
Tolmetin—Oedema—Hydrocortisone—psoriasis	8.86e-05	0.00152	CcSEcCtD
Tolmetin—Anaphylactic shock—Hydrocortisone—psoriasis	8.86e-05	0.00152	CcSEcCtD
Tolmetin—Asthenia—Mycophenolic acid—psoriasis	8.84e-05	0.00151	CcSEcCtD
Tolmetin—Dyspepsia—Cyclosporine—psoriasis	8.77e-05	0.0015	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—IL6—psoriasis	8.76e-05	0.00207	CbGpPWpGaD
Tolmetin—Nausea—Hydroxyurea—psoriasis	8.74e-05	0.0015	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	8.7e-05	0.00206	CbGpPWpGaD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—CP—psoriasis	8.69e-05	0.00206	CbGpPWpGaD
Tolmetin—Somnolence—Mycophenolate mofetil—psoriasis	8.64e-05	0.00148	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—psoriasis	8.64e-05	0.00148	CcSEcCtD
Tolmetin—MPO—Selenium Micronutrient Network—TNF—psoriasis	8.62e-05	0.00204	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IFNG—psoriasis	8.58e-05	0.00203	CbGpPWpGaD
Tolmetin—Dyspepsia—Mycophenolate mofetil—psoriasis	8.56e-05	0.00146	CcSEcCtD
Tolmetin—Constipation—Cyclosporine—psoriasis	8.52e-05	0.00146	CcSEcCtD
Tolmetin—CXCL8—TSLP Signaling Pathway—IL6—psoriasis	8.52e-05	0.00202	CbGpPWpGaD
Tolmetin—Renal failure—Methotrexate—psoriasis	8.49e-05	0.00145	CcSEcCtD
Tolmetin—Diarrhoea—Mycophenolic acid—psoriasis	8.43e-05	0.00144	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—psoriasis	8.42e-05	0.00144	CcSEcCtD
Tolmetin—Anaphylactic shock—Triamcinolone—psoriasis	8.34e-05	0.00143	CcSEcCtD
Tolmetin—Oedema—Triamcinolone—psoriasis	8.34e-05	0.00143	CcSEcCtD
Tolmetin—Constipation—Mycophenolate mofetil—psoriasis	8.31e-05	0.00142	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	8.29e-05	0.00196	CbGpPWpGaD
Tolmetin—Haematuria—Methotrexate—psoriasis	8.23e-05	0.00141	CcSEcCtD
Tolmetin—Gastrointestinal pain—Cyclosporine—psoriasis	8.15e-05	0.0014	CcSEcCtD
Tolmetin—Dizziness—Mycophenolic acid—psoriasis	8.15e-05	0.00139	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—psoriasis	8.15e-05	0.00139	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—VEGFA—psoriasis	8.13e-05	0.00193	CbGpPWpGaD
Tolmetin—Agranulocytosis—Methotrexate—psoriasis	8.06e-05	0.00138	CcSEcCtD
Tolmetin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.95e-05	0.00136	CcSEcCtD
Tolmetin—CXCL8—Corticotropin-releasing hormone—NFKB1—psoriasis	7.93e-05	0.00188	CbGpPWpGaD
Tolmetin—Urticaria—Cyclosporine—psoriasis	7.92e-05	0.00136	CcSEcCtD
Tolmetin—PTGS1—tendon—psoriasis	7.88e-05	0.026	CbGeAlD
Tolmetin—Body temperature increased—Cyclosporine—psoriasis	7.88e-05	0.00135	CcSEcCtD
Tolmetin—Abdominal pain—Cyclosporine—psoriasis	7.88e-05	0.00135	CcSEcCtD
Tolmetin—Vomiting—Mycophenolic acid—psoriasis	7.83e-05	0.00134	CcSEcCtD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	7.82e-05	0.00185	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—IFNG—psoriasis	7.81e-05	0.00185	CbGpPWpGaD
Tolmetin—Dyspepsia—Hydrocortisone—psoriasis	7.8e-05	0.00133	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	7.79e-05	0.00185	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	7.79e-05	0.00185	CbGpPWpGaD
Tolmetin—Hepatitis—Methotrexate—psoriasis	7.75e-05	0.00133	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	7.72e-05	0.0346	CbGdCrCtD
Tolmetin—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	7.72e-05	0.0346	CbGdCrCtD
Tolmetin—Urticaria—Mycophenolate mofetil—psoriasis	7.72e-05	0.00132	CcSEcCtD
Tolmetin—Headache—Mycophenolic acid—psoriasis	7.72e-05	0.00132	CcSEcCtD
Tolmetin—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	7.7e-05	0.00183	CbGpPWpGaD
Tolmetin—Body temperature increased—Mycophenolate mofetil—psoriasis	7.69e-05	0.00132	CcSEcCtD
Tolmetin—Abdominal pain—Mycophenolate mofetil—psoriasis	7.69e-05	0.00132	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—JUN—psoriasis	7.59e-05	0.0018	CbGpPWpGaD
Tolmetin—Oedema—Dexamethasone—psoriasis	7.57e-05	0.0013	CcSEcCtD
Tolmetin—Anaphylactic shock—Dexamethasone—psoriasis	7.57e-05	0.0013	CcSEcCtD
Tolmetin—Anaphylactic shock—Betamethasone—psoriasis	7.57e-05	0.0013	CcSEcCtD
Tolmetin—Oedema—Betamethasone—psoriasis	7.57e-05	0.0013	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	7.55e-05	0.0338	CbGdCrCtD
Tolmetin—PTGS2—tendon—psoriasis	7.53e-05	0.0248	CbGeAlD
Tolmetin—Visual impairment—Methotrexate—psoriasis	7.47e-05	0.00128	CcSEcCtD
Tolmetin—TDO2—Metabolism—CARM1—psoriasis	7.43e-05	0.00176	CbGpPWpGaD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—JUN—psoriasis	7.41e-05	0.00176	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—JUN—psoriasis	7.41e-05	0.00176	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Dexamethasone—psoriasis	7.41e-05	0.00127	CcSEcCtD
Tolmetin—Thrombocytopenia—Betamethasone—psoriasis	7.41e-05	0.00127	CcSEcCtD
Tolmetin—CXCL8—Cellular responses to stress—CAT—psoriasis	7.39e-05	0.00175	CbGpPWpGaD
Tolmetin—Dyspepsia—Triamcinolone—psoriasis	7.34e-05	0.00126	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—psoriasis	7.33e-05	0.00125	CcSEcCtD
Tolmetin—Nausea—Mycophenolic acid—psoriasis	7.32e-05	0.00125	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	7.3e-05	0.00173	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Hydrocortisone—psoriasis	7.24e-05	0.00124	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—psoriasis	7.23e-05	0.00124	CcSEcCtD
Tolmetin—Urticaria—Prednisolone—psoriasis	7.2e-05	0.00123	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	7.16e-05	0.0017	CbGpPWpGaD
Tolmetin—Asthenia—Cyclosporine—psoriasis	7.15e-05	0.00122	CcSEcCtD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—NFKB1—psoriasis	7.14e-05	0.00169	CbGpPWpGaD
Tolmetin—CXCL8—ATF-2 transcription factor network—IL6—psoriasis	7.1e-05	0.00168	CbGpPWpGaD
Tolmetin—Urticaria—Hydrocortisone—psoriasis	7.04e-05	0.0012	CcSEcCtD
Tolmetin—Body temperature increased—Hydrocortisone—psoriasis	7e-05	0.0012	CcSEcCtD
Tolmetin—Abdominal pain—Hydrocortisone—psoriasis	7e-05	0.0012	CcSEcCtD
Tolmetin—Asthenia—Mycophenolate mofetil—psoriasis	6.98e-05	0.00119	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—TNF—psoriasis	6.97e-05	0.00165	CbGpPWpGaD
Tolmetin—MPO—Selenium Micronutrient Network—IL6—psoriasis	6.96e-05	0.00165	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—REN—psoriasis	6.92e-05	0.00164	CbGpPWpGaD
Tolmetin—Diarrhoea—Cyclosporine—psoriasis	6.82e-05	0.00117	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	6.8e-05	0.00161	CbGpPWpGaD
Tolmetin—CXCL8—AP-1 transcription factor network—TP53—psoriasis	6.77e-05	0.0016	CbGpPWpGaD
Tolmetin—Dyspepsia—Dexamethasone—psoriasis	6.66e-05	0.00114	CcSEcCtD
Tolmetin—Dyspepsia—Betamethasone—psoriasis	6.66e-05	0.00114	CcSEcCtD
Tolmetin—Diarrhoea—Mycophenolate mofetil—psoriasis	6.65e-05	0.00114	CcSEcCtD
Tolmetin—Urticaria—Triamcinolone—psoriasis	6.63e-05	0.00113	CcSEcCtD
Tolmetin—Body temperature increased—Triamcinolone—psoriasis	6.59e-05	0.00113	CcSEcCtD
Tolmetin—Dizziness—Cyclosporine—psoriasis	6.59e-05	0.00113	CcSEcCtD
Tolmetin—Anaphylactic shock—Prednisone—psoriasis	6.59e-05	0.00113	CcSEcCtD
Tolmetin—Oedema—Prednisone—psoriasis	6.59e-05	0.00113	CcSEcCtD
Tolmetin—Dizziness—Mycophenolate mofetil—psoriasis	6.43e-05	0.0011	CcSEcCtD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—STAT3—psoriasis	6.41e-05	0.00152	CbGpPWpGaD
Tolmetin—Asthenia—Hydrocortisone—psoriasis	6.35e-05	0.00109	CcSEcCtD
Tolmetin—Vomiting—Cyclosporine—psoriasis	6.34e-05	0.00108	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	6.32e-05	0.0015	CbGpPWpGaD
Tolmetin—Headache—Cyclosporine—psoriasis	6.24e-05	0.00107	CcSEcCtD
Tolmetin—CXCL8—AP-1 transcription factor network—IL6—psoriasis	6.2e-05	0.00147	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Dexamethasone—psoriasis	6.19e-05	0.00106	CcSEcCtD
Tolmetin—Gastrointestinal pain—Betamethasone—psoriasis	6.19e-05	0.00106	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	6.19e-05	0.00147	CbGpPWpGaD
Tolmetin—Vomiting—Mycophenolate mofetil—psoriasis	6.18e-05	0.00106	CcSEcCtD
Tolmetin—Headache—Mycophenolate mofetil—psoriasis	6.09e-05	0.00104	CcSEcCtD
Tolmetin—Diarrhoea—Hydrocortisone—psoriasis	6.06e-05	0.00104	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	6.05e-05	0.00143	CbGpPWpGaD
Tolmetin—Urticaria—Dexamethasone—psoriasis	6.01e-05	0.00103	CcSEcCtD
Tolmetin—Urticaria—Betamethasone—psoriasis	6.01e-05	0.00103	CcSEcCtD
Tolmetin—Dizziness—Prednisolone—psoriasis	6e-05	0.00103	CcSEcCtD
Tolmetin—Asthenia—Triamcinolone—psoriasis	5.98e-05	0.00102	CcSEcCtD
Tolmetin—Body temperature increased—Betamethasone—psoriasis	5.98e-05	0.00102	CcSEcCtD
Tolmetin—Body temperature increased—Dexamethasone—psoriasis	5.98e-05	0.00102	CcSEcCtD
Tolmetin—Abdominal pain—Betamethasone—psoriasis	5.98e-05	0.00102	CcSEcCtD
Tolmetin—Abdominal pain—Dexamethasone—psoriasis	5.98e-05	0.00102	CcSEcCtD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—TP53—psoriasis	5.96e-05	0.00141	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	5.92e-05	0.0014	CbGpPWpGaD
Tolmetin—Nausea—Cyclosporine—psoriasis	5.92e-05	0.00101	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	5.88e-05	0.00139	CbGpPWpGaD
Tolmetin—Dizziness—Hydrocortisone—psoriasis	5.86e-05	0.001	CcSEcCtD
Tolmetin—Dyspepsia—Prednisone—psoriasis	5.8e-05	0.000993	CcSEcCtD
Tolmetin—Nausea—Mycophenolate mofetil—psoriasis	5.77e-05	0.000988	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—psoriasis	5.75e-05	0.000983	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	5.7e-05	0.00135	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	5.69e-05	0.00135	CbGpPWpGaD
Tolmetin—Headache—Prednisolone—psoriasis	5.68e-05	0.000973	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—TNF—psoriasis	5.68e-05	0.00135	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL4—psoriasis	5.66e-05	0.00134	CbGpPWpGaD
Tolmetin—Constipation—Prednisone—psoriasis	5.64e-05	0.000965	CcSEcCtD
Tolmetin—Vomiting—Hydrocortisone—psoriasis	5.63e-05	0.000964	CcSEcCtD
Tolmetin—Headache—Hydrocortisone—psoriasis	5.55e-05	0.00095	CcSEcCtD
Tolmetin—Dizziness—Triamcinolone—psoriasis	5.52e-05	0.000944	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—psoriasis	5.51e-05	0.000943	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	5.49e-05	0.0013	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—HCAR2—psoriasis	5.48e-05	0.0013	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IL6—psoriasis	5.46e-05	0.00129	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.45e-05	0.00129	CbGpPWpGaD
Tolmetin—Asthenia—Dexamethasone—psoriasis	5.43e-05	0.000929	CcSEcCtD
Tolmetin—Asthenia—Betamethasone—psoriasis	5.43e-05	0.000929	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—JUN—psoriasis	5.4e-05	0.00128	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Methotrexate—psoriasis	5.39e-05	0.000923	CcSEcCtD
Tolmetin—Gastrointestinal pain—Prednisone—psoriasis	5.39e-05	0.000922	CcSEcCtD
Tolmetin—Nausea—Prednisolone—psoriasis	5.39e-05	0.000922	CcSEcCtD
Tolmetin—CXCL8—GPCR downstream signaling—CCL20—psoriasis	5.3e-05	0.00126	CbGpPWpGaD
Tolmetin—Vomiting—Triamcinolone—psoriasis	5.3e-05	0.000908	CcSEcCtD
Tolmetin—Nausea—Hydrocortisone—psoriasis	5.26e-05	0.000901	CcSEcCtD
Tolmetin—Urticaria—Prednisone—psoriasis	5.24e-05	0.000896	CcSEcCtD
Tolmetin—Headache—Triamcinolone—psoriasis	5.22e-05	0.000894	CcSEcCtD
Tolmetin—Body temperature increased—Prednisone—psoriasis	5.21e-05	0.000892	CcSEcCtD
Tolmetin—Abdominal pain—Prednisone—psoriasis	5.21e-05	0.000892	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.2e-05	0.00123	CbGpPWpGaD
Tolmetin—Diarrhoea—Dexamethasone—psoriasis	5.18e-05	0.000886	CcSEcCtD
Tolmetin—Diarrhoea—Betamethasone—psoriasis	5.18e-05	0.000886	CcSEcCtD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	5.16e-05	0.00122	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TNF—psoriasis	5.06e-05	0.0012	CbGpPWpGaD
Tolmetin—Dizziness—Betamethasone—psoriasis	5e-05	0.000857	CcSEcCtD
Tolmetin—Dizziness—Dexamethasone—psoriasis	5e-05	0.000857	CcSEcCtD
Tolmetin—Nausea—Triamcinolone—psoriasis	4.95e-05	0.000848	CcSEcCtD
Tolmetin—Somnolence—Methotrexate—psoriasis	4.9e-05	0.000838	CcSEcCtD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—TP53—psoriasis	4.89e-05	0.00116	CbGpPWpGaD
Tolmetin—Dyspepsia—Methotrexate—psoriasis	4.85e-05	0.00083	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—CCL20—psoriasis	4.82e-05	0.00114	CbGpPWpGaD
Tolmetin—Vomiting—Dexamethasone—psoriasis	4.81e-05	0.000824	CcSEcCtD
Tolmetin—Vomiting—Betamethasone—psoriasis	4.81e-05	0.000824	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—LEP—psoriasis	4.79e-05	0.00113	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TAGAP—psoriasis	4.75e-05	0.00113	CbGpPWpGaD
Tolmetin—Headache—Betamethasone—psoriasis	4.74e-05	0.000811	CcSEcCtD
Tolmetin—Headache—Dexamethasone—psoriasis	4.74e-05	0.000811	CcSEcCtD
Tolmetin—Asthenia—Prednisone—psoriasis	4.73e-05	0.000809	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.72e-05	0.00112	CbGpPWpGaD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.71e-05	0.00111	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—JUN—psoriasis	4.69e-05	0.00111	CbGpPWpGaD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IL6—psoriasis	4.58e-05	0.00109	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—CAT—psoriasis	4.57e-05	0.00108	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.54e-05	0.00107	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—NFKB1—psoriasis	4.52e-05	0.00107	CbGpPWpGaD
Tolmetin—Diarrhoea—Prednisone—psoriasis	4.51e-05	0.000772	CcSEcCtD
Tolmetin—Gastrointestinal pain—Methotrexate—psoriasis	4.5e-05	0.000771	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	4.5e-05	0.00107	CbGpPWpGaD
Tolmetin—Nausea—Betamethasone—psoriasis	4.49e-05	0.000769	CcSEcCtD
Tolmetin—Nausea—Dexamethasone—psoriasis	4.49e-05	0.000769	CcSEcCtD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—IL6—psoriasis	4.48e-05	0.00106	CbGpPWpGaD
Tolmetin—CXCL8—Senescence and Autophagy in Cancer—IL6—psoriasis	4.48e-05	0.00106	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—NOS2—psoriasis	4.46e-05	0.00106	CbGpPWpGaD
Tolmetin—CXCL8—Spinal Cord Injury—TP53—psoriasis	4.46e-05	0.00106	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	4.44e-05	0.00105	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—CP—psoriasis	4.42e-05	0.00105	CbGpPWpGaD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	4.4e-05	0.00104	CbGpPWpGaD
Tolmetin—Urticaria—Methotrexate—psoriasis	4.38e-05	0.000749	CcSEcCtD
Tolmetin—Dizziness—Prednisone—psoriasis	4.36e-05	0.000746	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—psoriasis	4.35e-05	0.000745	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—psoriasis	4.35e-05	0.000745	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—CD4—psoriasis	4.34e-05	0.00103	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	4.33e-05	0.00103	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—ACE—psoriasis	4.32e-05	0.00102	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—CARM1—psoriasis	4.21e-05	0.000998	CbGpPWpGaD
Tolmetin—Vomiting—Prednisone—psoriasis	4.19e-05	0.000717	CcSEcCtD
Tolmetin—Headache—Prednisone—psoriasis	4.13e-05	0.000707	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—IL6—psoriasis	4.08e-05	0.000967	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—STAT3—psoriasis	4.06e-05	0.000962	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—TNF—psoriasis	4.04e-05	0.000958	CbGpPWpGaD
Tolmetin—Asthenia—Methotrexate—psoriasis	3.95e-05	0.000676	CcSEcCtD
Tolmetin—Nausea—Prednisone—psoriasis	3.91e-05	0.00067	CcSEcCtD
Tolmetin—PTGS1—Metabolism—NDUFA5—psoriasis	3.85e-05	0.000911	CbGpPWpGaD
Tolmetin—Diarrhoea—Methotrexate—psoriasis	3.77e-05	0.000645	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—psoriasis	3.64e-05	0.000623	CcSEcCtD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.61e-05	0.000856	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	3.6e-05	0.000853	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.59e-05	0.000849	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	3.58e-05	0.000848	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—APOE—psoriasis	3.55e-05	0.000841	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—JUN—psoriasis	3.55e-05	0.00084	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.53e-05	0.000836	CbGpPWpGaD
Tolmetin—Vomiting—Methotrexate—psoriasis	3.5e-05	0.000599	CcSEcCtD
Tolmetin—Headache—Methotrexate—psoriasis	3.45e-05	0.000591	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.42e-05	0.000811	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—NFKB1—psoriasis	3.41e-05	0.000809	CbGpPWpGaD
Tolmetin—Nausea—Methotrexate—psoriasis	3.27e-05	0.00056	CcSEcCtD
Tolmetin—PTGS1—Metabolism—CYP2S1—psoriasis	3.27e-05	0.000774	CbGpPWpGaD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL6—psoriasis	3.26e-05	0.000773	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	3.18e-05	0.000754	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—VEGFA—psoriasis	3.1e-05	0.000734	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—TP53—psoriasis	3.1e-05	0.000734	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—PPARG—psoriasis	3.09e-05	0.000732	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—STAT3—psoriasis	3.07e-05	0.000727	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—NDUFA5—psoriasis	3.05e-05	0.000723	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	3.04e-05	0.000719	CbGpPWpGaD
Tolmetin—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.85e-05	0.000674	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.85e-05	0.000674	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—CCL20—psoriasis	2.85e-05	0.000674	CbGpPWpGaD
Tolmetin—CXCL8—Cellular Senescence—IL6—psoriasis	2.84e-05	0.000672	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.8e-05	0.000663	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—LEP—psoriasis	2.68e-05	0.000636	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CYP2S1—psoriasis	2.6e-05	0.000615	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—TP53—psoriasis	2.34e-05	0.000554	CbGpPWpGaD
Tolmetin—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	2.26e-05	0.000535	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TNF—psoriasis	2.21e-05	0.000525	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—IL6—psoriasis	2.14e-05	0.000508	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.01e-05	0.000477	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.95e-05	0.000463	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.94e-05	0.000459	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.79e-05	0.000423	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.76e-05	0.000416	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.71e-05	0.000406	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CARM1—psoriasis	1.6e-05	0.000378	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—SOCS1—psoriasis	1.57e-05	0.000371	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.51e-05	0.000357	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—TYK2—psoriasis	1.49e-05	0.000354	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.49e-05	0.000354	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.36e-05	0.000322	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.33e-05	0.000315	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CARM1—psoriasis	1.27e-05	0.0003	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.18e-05	0.000281	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—APOE—psoriasis	1.16e-05	0.000274	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—LEP—psoriasis	1.16e-05	0.000274	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NFKBIA—psoriasis	1.08e-05	0.000255	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—CAT—psoriasis	9.82e-06	0.000233	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TYK2—psoriasis	8.82e-06	0.000209	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—CAT—psoriasis	7.8e-06	0.000185	CbGpPWpGaD
Tolmetin—PTGS2—Disease—HLA-A—psoriasis	7.75e-06	0.000184	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—APOE—psoriasis	7.63e-06	0.000181	CbGpPWpGaD
Tolmetin—CXCL8—Signaling by GPCR—IL6—psoriasis	7.31e-06	0.000173	CbGpPWpGaD
Tolmetin—PTGS2—Disease—APOE—psoriasis	7.23e-06	0.000171	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—JUN—psoriasis	7.14e-06	0.000169	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—NFKB1—psoriasis	6.88e-06	0.000163	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NOS2—psoriasis	6.74e-06	0.00016	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—PPARG—psoriasis	6.65e-06	0.000157	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—VEGFA—psoriasis	6.24e-06	0.000148	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—STAT3—psoriasis	6.18e-06	0.000146	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—APOE—psoriasis	6.06e-06	0.000143	CbGpPWpGaD
Tolmetin—PTGS2—Disease—TYK2—psoriasis	5.52e-06	0.000131	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—PPARG—psoriasis	5.28e-06	0.000125	CbGpPWpGaD
Tolmetin—PTGS2—Disease—CD4—psoriasis	4.99e-06	0.000118	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—TP53—psoriasis	4.72e-06	0.000112	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—IL6—psoriasis	4.32e-06	0.000102	CbGpPWpGaD
Tolmetin—PTGS2—Disease—STAT3—psoriasis	3.87e-06	9.16e-05	CbGpPWpGaD
Tolmetin—PTGS2—Disease—IL6—psoriasis	2.7e-06	6.4e-05	CbGpPWpGaD
